Invasight is a Swiss-based pre-clinical stage biotech start-up that develops first-in-class, protein-protein interaction antagonists (PPIAs) against invasive cancers. Our breakthrough drug discovery platform, ACINDA accelerates drug discovery and enables precise design of small molecule PPIAs against specific proteins, which cause cancer cell invasion.
Invasight AG
